Tirzepatide, LY3298176 and the short name tirze belong to one catalog entry. Retatrutide uses the code LY3437943. This guide shows what the database records state and where the catalog details are.
PubChem CID 156588324 is titled Tirzepatide. MeSH lists LY3298176 as an entry term for the same record. ChEBI CHEBI:194186 lists LY3298176 and LY-3298176 as synonyms, and both records give CAS number 2023788-19-2.
In the catalog, the short name tirze is the Tirzepatide product entry, not an extra ingredient. A short name is not a complete material identification. Connect it to the product name and to documents that are actually published for that entry.
Both records give the formula C225H348N48O68. PubChem shows a molecular weight of 4813 g/mol. ChEBI lists an average mass of 4813.527 for the same formula. ChEBI describes a 39-amino-acid linear polypeptide conjugated to a C20 fatty-diacid moiety through a linker at lysine-20.
Those lines identify the database record. They do not state the salt form, amount or contents of a particular vial, and they are not an analysis document for a catalog product.
PubChem and ChEBI describe Tirzepatide in relation to the GIP receptor and the GLP-1 receptor. Dual agonist means two receptor targets for one molecule. It does not mean the package contains two peptides.
Retatrutide is a different record. Coskun and colleagues described that molecule under the code LY3437943. Its description also includes the glucagon receptor. The same unit in mg, or two cards sitting next to each other in the catalog, does not make the substances interchangeable.
The link below goes to the Tirzepatide catalog entry. That page states the name, formats and price that can be ordered. Analytical values appear only when a document is published. The database records above do not verify the store’s material.
This guide is about separating two names and two codes. It does not describe dosing, preparation or use in humans or animals.
For laboratory research only. Not for human or veterinary use.